Information  X 
Enter a valid email address

Celtic PLC (CCP)

  Print          Annual reports

Friday 31 August, 2018

Celtic PLC

Issue of Equity

RNS Number : 3188Z
Celtic PLC
31 August 2018
 

CELTIC PLC

Issued share capital

 

As a result of the issue on 31 August 2018 of 50,615 Ordinary Shares of 1p each ("Ordinary Shares") under the Company's scrip dividend reinvestment scheme, Celtic PLC's issued share capital as at 31 August 2018 will be as follows:

 

93,850,670           Ordinary Shares of 1p each                         

12,907,679           Convertible Preferred Ordinary Shares of 100p each ("CPO Shares")

15,912,945           Convertible Cumulative Preference Shares of 60p each ("CCP Shares")

652,495,236         Deferred Shares of 1p each ("Deferred Shares")

 

CCP Shares do not carry voting rights. Deferred Shares are not listed, are not transferable and carry no voting rights or substantive economic rights. 

 

The above figures for Ordinary Shares and CPO Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in voting rights under the FCA's Disclosure Guidance and Transparency Rules.

 

The new Ordinary Shares of 1p each allotted under the scrip scheme have been issued at a notional price of 131.2p each.

 

Application has been made for the admission of the 50,615 new Ordinary Shares of 1p each ("New Ordinary Shares") to trading on AIM. It is expected that dealings in these New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, will commence on 6 September 2018.

 

Enquiries:

 

Company

Michael Nicholson, Company Secretary                 0141 551 4298

 

Canaccord Genuity Limited

Simon Bridges, Nominated Adviser                         020 7523 8350

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOEEBLFXVVFXBBV

a d v e r t i s e m e n t